Evidence map›Paper›PMID 36423938›Full record

ArticleBMJ case reports2022

Odynophagia as the first manifestation of toxic epidermal necrolysis.

Noelia Ortega Beltrá, Fernando Guallart Domenech, Paula Martínez Ruiz de Apodaca, Francisco Pons Rocher

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Noelia Ortega BeltráOtorhinolaryngology, Hospital Universitario Doctor Peset, Valencia, Spain.
Fernando Guallart DomenechOtorhinolaryngology, Hospital Universitario Doctor Peset, Valencia, Spain.
Paula Martínez Ruiz de ApodacaOtorhinolaryngology, Hospital Universitario Doctor Peset, Valencia, Spain.
Francisco Pons RocherOtorhinolaryngology, Hospital Universitario Doctor Peset, Valencia, Spain francisco.rocher@uv.es.ORCID http://orcid.org/0000-0002-6574-1550
Hospital Universitario Doctor Peset · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are infrequent mucocutaneous diseases, rapidly progressive and life-threatening. The clinical aspects and the management of TEN are exposed following a case.A man in his 40s presented to the emergency department with severe odynophagia, poor general condition and fever. His medical history was significant for HIV stage AIDS, and the treatment was discontinued 5 years before the present diagnosis. He was admitted for cerebral toxoplasmosis and discharged the previous 14 days with sulfadiazine. Erythematous-bullous lesions in the oral cavity, diffuse erythematous maculopapular rashes over his neck and chest, acute bilateral conjunctivitis and purulent urethritis was observed. The diagnostic suspicion was SJS/TEN due to sulfadiazine in immunosuppressed patients.This entity is infrequent but is a life-threatening dermatological emergency that requires immediate medical attention. Its diagnosis is mainly clinical, with a new drug history, prodromal symptoms and characteristic cutaneous-mucous lesions. Early diagnosis and rapid withdrawal of the drug improve the prognosis.

Indexed as

Deglutition DisordersStevens-Johnson SyndromeAcute DiseaseHumansMalePainSulfadiazineSulfadiazinedermatologydrugs and medicinesear, nose and throatHIV / AIDSsafety

Identifiers

PMID36423938
PMCPMC9693651
OpenAlexW4309886987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.